Thursday, August 17, 2017 12:01:50 PM
SNMX 0.60 MY NEX EBIO BCRX 1000% BIOTECH TURN AROUND TICKET.... EXTREMLY UNDERVALUED IMO!! CHECK IT OUT >>>>>
Financial Results:
Commercial revenues increased 24% to $2.8 million in the second quarter ended June 30, 2017. For the six months ended June 30, 2017, commercial revenues increased 25% to $5.5 million. These improvements primarily resulted from higher direct sales of flavor ingredients to flavor houses and higher royalties from sweet taste boosting ingredients
Financial Outlook:
Senomyx ended the second quarter 2017 with no debt and $11.2 million in cash, an increase of $1.1 million during the second quarter. In addition, the Company is scheduled to receive $14.0 million in committed development funding in the future.
For the third quarter of 2017, the Company expects:
Revenues to be at least $4.7 million, of which at least $2.9 million are commercial revenues; and
Net loss not to exceed $3.2 million or $0.07 per share
Financial Results:
Commercial revenues increased 24% to $2.8 million in the second quarter ended June 30, 2017. For the six months ended June 30, 2017, commercial revenues increased 25% to $5.5 million. These improvements primarily resulted from higher direct sales of flavor ingredients to flavor houses and higher royalties from sweet taste boosting ingredients
Financial Outlook:
Senomyx ended the second quarter 2017 with no debt and $11.2 million in cash, an increase of $1.1 million during the second quarter. In addition, the Company is scheduled to receive $14.0 million in committed development funding in the future.
For the third quarter of 2017, the Company expects:
Revenues to be at least $4.7 million, of which at least $2.9 million are commercial revenues; and
Net loss not to exceed $3.2 million or $0.07 per share
Join the InvestorsHub Community
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
